ID   LN-464
AC   CVCL_3962
SY   LN 464; LN464
DR   BTO; BTO:0004451
DR   BioSample; SAMN10988403
DR   cancercelllines; CVCL_3962
DR   Cell_Model_Passport; SIDM00058
DR   Cosmic; 849873
DR   Cosmic; 2367498
DR   Cosmic; 2516032
DR   DepMap; ACH-000676
DR   PharmacoDB; LN464_848_2019
DR   Wikidata; Q54902786
RX   PubMed=7693337;
RX   PubMed=8509230;
RX   PubMed=10416987;
RX   PubMed=22570425;
RX   PubMed=25984343;
RX   PubMed=31068700;
CC   Problematic cell line: Contaminated. The STR profile of ACN and LN-464 are identical. SNP analysis (DepMap) also shows identity of both cell lines. Personal communication from Hegi M. confirms the mismatch between the STR profile of this cell line and of the patient from which LN-464 was established. We believe this is a melanoma cell line based on the RNASeq expression profile of LN-464 (DepMap) which clusters with that of melanoma patient samples. The presence of the BRAF V600E while present at low frequency in gliomas is also a hallmark of melanomas. Originally thought to originate from the brain right parieto-occipital lobe of a 67 year old male patient with a glioblastoma.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 35 hours (PubMed=25984343).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn184fs*6 (c.545_546insA); Zygosity=Heterozygous (PubMed=10416987; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Ser (c.338T>C); ClinVar=VCV000823709; Zygosity=Homozygous (PubMed=10416987; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: shRNA library screening.
ST   Source(s): PubMed=22570425
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,13
ST   D16S539: 11
ST   D18S51: 16
ST   D21S11: 28
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 10,13
ST   D8S1179: 12,13
ST   FGA: 22
ST   Penta D: 9
ST   Penta E: 10,14
ST   TH01: 9
ST   TPOX: 9,12
ST   vWA: 14,17,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1068 ! ACN
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 22
//
RX   PubMed=7693337;
RA   Li H., Hamou M.-F., de Tribolet N., Jaufeerally R., Hofmann M.,
RA   Diserens A.-C., Van Meir E.G.;
RT   "Variant CD44 adhesion molecules are expressed in human brain
RT   metastases but not in glioblastomas.";
RL   Cancer Res. 53:5345-5349(1993).
//
RX   PubMed=8509230; DOI=10.1002/ijc.2910540329;
RA   Rimoldi D., Romero P., Carrel S.;
RT   "The human melanoma antigen-encoding gene, MAGE-1, is expressed by
RT   other tumour cells of neuroectodermal origin such as glioblastomas and
RT   neuroblastomas.";
RL   Int. J. Cancer 54:527-528(1993).
//
RX   PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x;
RA   Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C.,
RA   Van Meir E.G.;
RT   "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor
RT   suppressor genes in human glioma cell lines.";
RL   Brain Pathol. 9:469-479(1999).
//
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//